Descriptive Statistics of Serum Concentrations of Cytokines, Lipopolysaccharides and Cardiac Troponin by Severity Stage in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).

Descriptive Statistics of Serum Concentrations of Cytokines, Lipopolysaccharides and Cardiac Troponin by Severity Stage in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).

<p>Descriptive Statistics of Serum Concentrations of Cytokines, Lipopolysaccharides and Cardiac Troponin by Severity Stage in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).</p>

Збережено в:

Бібліографічні деталі
Автор:	Maria C. Jugan (18928389) (author)
Інші автори:	Gabrielle A. Rands (22676472) (author), Joerg M. Steiner (6887384) (author), Natalia Cernicchiaro (783181) (author), Matthew C. Tanner (22676475) (author), Lillian M. Novotny (22676478) (author)
Опубліковано:	2025
Предмети:	Medicine Microbiology Cell Biology Physiology Biotechnology Ecology Immunology Cancer Science Policy Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified muscle condition score linear regression models fisher exact test evaluate possible associations body condition score gastrointestinal barrier function inflammatory biomarkers based stage c disease gastrointestinal clinical signs lps ), interleukins including 25 dogs e ., il div >< p stage b2 disease gastrointestinal bacterial translocation group 2 ), mmvd stage severity gastrointestinal signs bacterial translocation b2 disease gastrointestinal microbiome inflammatory markers disease progresses cardiovascular disease group 2 group 1 xlink "> untreated mmvd twenty percent therapeutic targets study indicates study aimed spearman ’ six client serum lps serum lipopolysaccharide serum il potential relationship positively correlated owned dogs mmvd severity mmvd ). maybe even groups 1 findings warrant fecal scores enrolled prospectively echocardiographic diagnosis compare proportions compare lps
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Association between Exposures of Interest with Serum Lipopolysaccharide and Troponin Concentrations Based on Univariable Models‡ in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).
за авторством: Maria C. Jugan (18928389)
Опубліковано: (2025)

Spearman correlation coefficient (r<sub>s</sub>) between echocardiographic measurements (i.e., left atrial:aortic root diameter; LA:Ao), markers of loss of GI barrier function (i.e., lipopolysaccharide; LPS), and cardiac (i.e., troponin) and systemic (i.e., cytokines) inflammation in 36 dogs with untreated myxomatous mitral valve disease (MMVD).
за авторством: Maria C. Jugan (18928389)
Опубліковано: (2025)

Association between Exposures of Interest with Serum Cytokine Concentrations Based on Univariable Models‡ in 36 Client-owned Dogs with Untreated Myxomatous Mitral Valve Disease (MMVD).
за авторством: Maria C. Jugan (18928389)
Опубліковано: (2025)

Structural Basis of Lipopolysaccharide Assembly by the Outer Membrane Translocon Holo-Complex
за авторством: Rémi Fronzes (427447)
Опубліковано: (2025)

Comparison of WPAI-GH and SF-36v2 scores between normal and severe groups classified by dysmenorrhea score.
за авторством: Maika Nariai (22676447)
Опубліковано: (2025)

Participant characteristics in the overall cohort and in groups classified by dysmenorrhea score.
за авторством: Maika Nariai (22676447)
Опубліковано: (2025)

Multiple regression analyses of factors associated with work productivity and QoL.
за авторством: Maika Nariai (22676447)
Опубліковано: (2025)

Comparison of work productivity and QoL between women with normal and severe dysmenorrhea scores.
за авторством: Maika Nariai (22676447)
Опубліковано: (2025)

Relationship between dysmenorrhea score and presenteeism, activity impairment, physical component summary (PCS), mental component summary (MCS), and role/social component summary (RCS) scores.
за авторством: Maika Nariai (22676447)
Опубліковано: (2025)

Medication-inclusive multivariable logistic regression for MAFLD.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Multivariable logistic regression models for MAFLD predictors.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Liver Fibrosis Characteristics by CKD Stage in MAFLD Patients (n = 64).
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Liver Stiffness and Fibrosis Grading by MAFLD Status.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Comparison of Non-invasive Liver Fibrosis Scores.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Demographic and Clinical Characteristics of Study Participants.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Proposed pathophysiological crosstalk between MAFLD and CKD.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Receiver operating characteristic (ROC) curve analysis comparing the performance of non-invasive fibrosis scores in MAFLD patients.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Stratification of Liver Stiffness according to eGFR in the MAFLD group.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

A. Violin plots showing eGFR distribution in MAFLD (red) vs. non-MAFLD (blue) groups.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Grades of liver fibrosis in MAFLD group (grey) and non-MAFLD group (black).
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

eGFR in the study participants.
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

2D–shear-wave elastography example: MAFLD + CKD case (female, 57 years).
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

2D–shear-wave elastography example: MAFLD + CKD case (male, 65 years).
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

2D–shear-wave elastography example: non-MAFLD CKD case (male, 54 years).
за авторством: Zienab M. Saad (22676502)
Опубліковано: (2025)

Comparison of hierarchical classifier performance among four machine learning models for the early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of multi-class classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of binary classifier performance among four machine learning models for early-loss, intermediate-loss, and late/no-loss groups.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of performance of four machine learning models for long-term graft loss prediction.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of prediction performance with previously reported metrics.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Comparison of performance of four machine learning models for early graft loss prediction.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Predicting stratified groups in the validation cohort: (A) Workflows for the multi-class classification and hierarchical classification models are illustrated.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Stratification and characterization of groups showing different graft survival: (A) UMAP visualization of the stratified derivation cohort data based on the distance matrix from the RF clustering.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Prediction of early graft loss at the individual level and identification of crucial factors: (A) Survival curves for all patients who experienced graft loss are plotted.
за авторством: Raiki Yoshimura (22676573)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Characteristic Flavaglines with Therapeutic Potential for Ischemic Stroke from <i>Aglaia perviridis</i>
за авторством: Yan-Ping Zhang (432349)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_118tik9mtuusn2242s95lcp6du